Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Post by losingmyshirton Jan 06, 2022 10:40am
172 Views
Post# 34288928

Sad but true.

Sad but true.@malarkey Fake News Clitaris Announces Strategy for the Nitric Oxide Formula R812 for Enhanced Orgasms and Increased Sexual Desire. Sanfrancisco, CA and Toronna, On Jan 2022 Clitaris -- Stockgroup CLYt are pleased to announce plans for another new strategy to develop R812, this time for the enhancement of sexual pleasure. “CLYT is poised to accelerate the development of R812 so that soon both men and women can expect bigger and better orgasms.” Said Director LMShirt Phase 1 Study will be complete after it commences sometime this year, stay tooned. Phase 2 which is a multiple will commence sometime after Phase 1 is completed Phase 2C will be a multiple phase focussing on making it easier for men to achieve and maintain erections while women will experience increased natural lubrication. Mister Shirt continued “ Nitric oxide can have sexual health benefits, improve cardiovascular health, promote energy level and moods, improve function and expedite recovery time.(wink, wink ) This is certainly what the world needs now” The Salesman Team were going to volunteer gratis but later decided to negotiate another Licence and have begun making room so that their sharecount is again less than 19%
<< Previous
Bullboard Posts
Next >>